Segall Bryant & Hamill LLC Decreases Stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Segall Bryant & Hamill LLC lessened its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 8.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 516,877 shares of the biotechnology company’s stock after selling 45,898 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Aurinia Pharmaceuticals were worth $4,642,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in AUPH. State Street Corp raised its position in shares of Aurinia Pharmaceuticals by 2.3% during the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock valued at $21,587,000 after buying an additional 64,949 shares in the last quarter. Vanguard Group Inc. raised its position in Aurinia Pharmaceuticals by 6.9% during the fourth quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company’s stock valued at $15,535,000 after purchasing an additional 112,113 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Aurinia Pharmaceuticals by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock valued at $5,454,000 after purchasing an additional 89,940 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Aurinia Pharmaceuticals by 22.5% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 556,454 shares of the biotechnology company’s stock worth $4,997,000 after purchasing an additional 102,195 shares during the period. Finally, PDT Partners LLC increased its position in shares of Aurinia Pharmaceuticals by 76.0% during the 3rd quarter. PDT Partners LLC now owns 301,553 shares of the biotechnology company’s stock valued at $2,210,000 after purchasing an additional 130,204 shares during the last quarter. Institutional investors own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday.

Insider Activity

In other news, CEO Peter Greenleaf sold 195,593 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the sale, the chief executive officer now directly owns 1,953,892 shares of the company’s stock, valued at approximately $15,631,136. The trade was a 9.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Greg Keenan sold 8,305 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $8.23, for a total transaction of $68,350.15. Following the completion of the transaction, the insider now directly owns 153,484 shares in the company, valued at $1,263,173.32. This represents a 5.13 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 343,898 shares of company stock valued at $2,753,094. 4.30% of the stock is currently owned by insiders.

Aurinia Pharmaceuticals Stock Performance

Aurinia Pharmaceuticals stock opened at $8.46 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The firm has a market capitalization of $1.16 billion, a P/E ratio of -56.40 and a beta of 1.26. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.71 and a 1-year high of $10.67. The company’s 50-day moving average is $8.09 and its 200 day moving average is $8.02.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.